BioSpace News Archive

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2023.

Humacyte, Inc. announced it will host a virtual KOL event on Thursday, March 28, 2024 at 8:00 AM ET, featuring Timmy Lee, MD, MSPH and Prabir Roy-Chaudhury MD, PhD, FRCP who will discuss the profiles of patients receiving an AV Access who have higher rates of complications and the associated costs of treating them.

Auburn University is now home to the world’s first field-installed, clinically approved Terra.X 7 Tesla magnetic resonance imaging scanner — expanding the window for cutting-edge research and public use.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

VESICA HEALTH, INC., a leading multi-omics liquid biopsy company dedicated to improving the management of hematuria patients and the early detection of bladder cancer had their urine-based biomarker featured in a recent peer-reviewed publication.

OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer, and Chief Financial Officer, are scheduled to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference.

Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced it will present at the upcoming 23rd Annual Needham Healthcare Conference being held virtually.

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported fourth quarter and full year 2023 financial results.

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, today reported financial results for the full year ended December 31, 2023, and reiterated its recent progress and anticipated milestones.

MannKind Corporation announced that Steven B. Binder will retire from his position as Chief Financial Officer, effective April 22, 2024.